合計 50 件の最近のインサイダー取引記録が記録されています Quest Diagnostics Incorporated (DGX), 内訳は 11 件の買い および 33 件の売り. インサイダー買い総額は $27.15M インサイダー売り総額は $28.42M.
最近活動のある主要インサイダーには Wentworth Timothy C, Prevoznik Michael E, Plewman Patrick. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — DGX
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-04-01 |
Wentworth Timothy C |
Director |
RSU 付与（制限付株式） |
198 |
- |
- |
198 |
| 2026-03-09 |
Wentworth Timothy C |
Director |
不明 |
- |
- |
- |
- |
| 2026-03-09 |
Wentworth Timothy C |
Director |
RSU 付与（制限付株式） |
215 |
- |
- |
215 |
| 2026-03-05 |
Prevoznik Michael E |
SVP & General Counsel |
情報に基づく売り |
3,878 |
$206.21 |
$799.68K |
37,557 |
| 2026-03-05 |
Plewman Patrick |
SVP For Diagnostic Services |
情報に基づく売り |
2,855 |
$206.21 |
$588.73K |
15,198 |
| 2026-03-05 |
Doherty Catherine T. |
EVP, Regional Businesses |
情報に基づく売り |
5,558 |
$206.21 |
$1.15M |
67,122 |
| 2026-03-04 |
Prevoznik Michael E |
SVP & General Counsel |
RSU 源泉徴収 |
3,354 |
$204.86 |
$687.1K |
41,435 |
| 2026-03-04 |
Plewman Patrick |
SVP For Diagnostic Services |
RSU 源泉徴収 |
2,827 |
$204.86 |
$579.14K |
18,053 |
| 2026-03-04 |
Doherty Catherine T. |
EVP, Regional Businesses |
RSU 源泉徴収 |
5,806 |
$204.86 |
$1.19M |
72,680 |
| 2026-03-04 |
Davis J. E. |
CEO and President |
RSU 源泉徴収 |
26,414 |
$204.86 |
$5.41M |
142,423 |
| 2026-03-04 |
Samad Sam |
Executive Vice President & CFO |
RSU 源泉徴収 |
7,720 |
$204.86 |
$1.58M |
33,268 |
| 2026-03-04 |
Deppe Michael J |
SVP, Corp. Controller & CAO |
RSU 源泉徴収 |
750 |
$204.86 |
$153.65K |
35,196 |
| 2026-03-04 |
Kuppusamy Karthik |
SVP, Clinical Solutions |
情報に基づく売り |
2,628 |
$204.86 |
$538.37K |
13,441 |
| 2026-03-04 |
Delaney Mark E |
SVP & Chief Commercial Officer |
RSU 源泉徴収 |
2,326 |
$204.86 |
$476.5K |
11,864 |
| 2026-03-03 |
Prevoznik Michael E |
SVP & General Counsel |
情報に基づく売り |
526 |
$207.73 |
$109.27K |
37,557 |
| 2026-03-03 |
Plewman Patrick |
SVP For Diagnostic Services |
情報に基づく売り |
410 |
$207.73 |
$85.17K |
15,198 |
| 2026-03-03 |
Doherty Catherine T. |
EVP, Regional Businesses |
情報に基づく売り |
632 |
$207.73 |
$131.29K |
67,122 |
| 2026-03-02 |
Prevoznik Michael E |
SVP & General Counsel |
RSU 源泉徴収 |
288 |
$204.86 |
$59K |
38,083 |
| 2026-03-02 |
Plewman Patrick |
SVP For Diagnostic Services |
RSU 源泉徴収 |
230 |
$204.86 |
$47.12K |
15,608 |
| 2026-03-02 |
Doherty Catherine T. |
EVP, Regional Businesses |
RSU 源泉徴収 |
648 |
$204.86 |
$132.75K |
67,754 |
| 2026-03-02 |
Davis J. E. |
CEO and President |
情報に基づく売り |
10,000 |
$212.52 |
$2.13M |
117,185 |
| 2026-03-02 |
Samad Sam |
Executive Vice President & CFO |
RSU 源泉徴収 |
869 |
$204.86 |
$178.02K |
27,041 |
| 2026-03-02 |
Deppe Michael J |
SVP, Corp. Controller & CAO |
RSU 源泉徴収 |
88 |
$204.86 |
$18.03K |
34,473 |
| 2026-03-02 |
Kuppusamy Karthik |
SVP, Clinical Solutions |
RSU 源泉徴収 |
205 |
$204.86 |
$42K |
9,869 |
| 2026-03-02 |
Delaney Mark E |
SVP & Chief Commercial Officer |
RSU 源泉徴収 |
188 |
$204.86 |
$38.51K |
8,508 |
| 2026-02-19 |
Prevoznik Michael E |
SVP & General Counsel |
情報に基づく売り |
1,111 |
$204.83 |
$227.57K |
38,371 |
| 2026-02-19 |
Plewman Patrick |
SVP For Diagnostic Services |
情報に基づく売り |
958 |
$204.83 |
$196.23K |
15,838 |
| 2026-02-19 |
Doherty Catherine T. |
EVP, Regional Businesses |
情報に基づく売り |
1,433 |
$204.83 |
$293.52K |
68,402 |
| 2026-02-18 |
Prevoznik Michael E |
SVP & General Counsel |
RSU 付与（制限付株式） |
9,289 |
$204.96 |
$1.9M |
9,289 |
| 2026-02-18 |
Plewman Patrick |
SVP For Diagnostic Services |
RSU 付与（制限付株式） |
9,009 |
$204.96 |
$1.85M |
9,009 |
| 2026-02-18 |
Doherty Catherine T. |
EVP, Regional Businesses |
RSU 付与（制限付株式） |
13,514 |
$204.96 |
$2.77M |
13,514 |
| 2026-02-18 |
Davis J. E. |
CEO and President |
RSU 付与（制限付株式） |
73,225 |
$204.96 |
$15.01M |
73,225 |
| 2026-02-18 |
Samad Sam |
Executive Vice President & CFO |
RSU 付与（制限付株式） |
18,303 |
$204.96 |
$3.75M |
18,303 |
| 2026-02-18 |
Deppe Michael J |
SVP, Corp. Controller & CAO |
RSU 付与（制限付株式） |
1,688 |
$204.96 |
$345.97K |
1,688 |
| 2026-02-18 |
Kuppusamy Karthik |
SVP, Clinical Solutions |
RSU 源泉徴収 |
259 |
$206.99 |
$53.61K |
7,914 |
| 2026-02-18 |
Delaney Mark E |
SVP & Chief Commercial Officer |
RSU 付与（制限付株式） |
7,332 |
$204.96 |
$1.5M |
7,332 |
| 2026-02-13 |
Doherty Catherine T. |
EVP, Regional Businesses |
オプション行使（売却） |
26,165 |
$112.17 |
$2.93M |
- |
| 2026-02-10 |
Plewman Patrick |
SVP For Diagnostic Services |
オプション行使（売却） |
5,662 |
$121.81 |
$689.66K |
- |
| 2026-01-28 |
Plewman Patrick |
SVP For Diagnostic Services |
RSU 付与（制限付株式） |
48 |
$183.51 |
$8.81K |
15,381 |
| 2026-01-28 |
Carter Robert B |
Director |
少額取引 |
6 |
$183.51 |
$1.1K |
2,704 |
| 2026-01-28 |
Gregg Vicky B |
Director |
少額取引 |
67 |
$183.51 |
$12.3K |
17,104 |
| 2026-01-28 |
Samad Sam |
Executive Vice President & CFO |
RSU 付与（制限付株式） |
69 |
$183.51 |
$12.66K |
27,910 |
| 2026-01-28 |
Lassiter Wright Iii |
Director |
少額取引 |
7 |
$183.51 |
$1.28K |
9,057 |
| 2026-01-28 |
Kuppusamy Karthik |
SVP, Clinical Solutions |
少額取引 |
16 |
$183.52 |
$2.94K |
10,065 |
| 2026-01-28 |
Delaney Mark E |
SVP & Chief Commercial Officer |
少額取引 |
15 |
$183.51 |
$2.75K |
8,696 |
| 2025-11-25 |
Gregg Vicky B |
Director |
情報に基づく売り |
1,250 |
$191.76 |
$239.7K |
17,037 |
| 2025-11-25 |
Davis J. E. |
CEO and President |
オプション行使（売却） |
55,093 |
$95.80 |
$5.28M |
- |
| 2025-11-18 |
Delaney Mark E |
SVP & Chief Commercial Officer |
オプション行使（売却） |
7,846 |
$144.47 |
$1.13M |
- |
| 2025-11-05 |
Davis J. E. |
CEO and President |
RSU 源泉徴収 |
7,143 |
$175.57 |
$1.25M |
120,480 |
| 2025-10-23 |
Pfeiffer Gary M |
Director |
裁量売り |
4,413 |
- |
- |
- |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
